Program
CRB-913
A development code.
Its studies are mostly in Obesity, led by Corbus Pharmaceuticals.
Furthest: phase 1, since Dec 16, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Corbus Pharmaceuticals | 10 open or running | phase 1since Dec 16, 2025 | Dec 16, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2025First study: phase 1 study in ObesityFirst studyNCT07310901 · 254 enrolled · United States
TargetBeta
CNR1 →read by rule
“CRB-913 is a novel cannabinoid receptor type 1 (CB1) inverse agonist (CB1-IA) that is being developed for once-daily treatment of obesity.”study text, by rule · the study
Other programs on CNR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Cannabidiolrule | Jazz Pharmaceuticals | phase 4 | 68 |
| Rimonabantrule | Sanofi | phase 3 | 38 |
| Dronabinolrule | Jazz Pharmaceuticals | phase 3 | 20 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07310901Obesity · United States | 1 | Completed | Aug 3, 2026 | 254 |
How it is read
Names in the registry
- “CRB-913”, 1 entry
Codes read as this program: CRB913.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.